Semisynthetic approaches to laspartomycin analogues

Area of Science:

• Microbiology
• Medicinal Chemistry
• Natural Products

Background:

• Laspartomycin C is a lipopeptide antibiotic structurally related to amphomycin.
• It possesses a cyclic peptide core, an external aspartic acid unit, and a C15-2,3-unsaturated fatty acid.
• Initial activity was against Staphylococcus aureus; recent studies show efficacy against vancomycin-resistant Enterococci (VRE), vancomycin-intermediate Staphylococcus aureus (VISA), and methicillin-resistant Staphylococcus aureus (MRSA).

Purpose of the Study:

• To investigate the structural requirements for the biological activity of Laspartomycin C.
• To explore the potential of Laspartomycin C derivatives as antibiotics against resistant bacterial strains.

Main Methods:

• Enzymatic cleavage of the fatty acid tail of Laspartomycin C using a deacylase from Actinoplanes utahensis.
• Generation of semisynthetic derivatives of the resulting peptides (Peptide 1 and Peptide 2).

Main Results:

• Enzymatic cleavage yielded two distinct peptides: Peptide 1 and Peptide 2.
• Semisynthetic modifications were successfully applied to both peptides.
• The presence of an acylaspartic acid moiety was identified as the principal requirement for maintaining biological activity.

Conclusions:

• The acylaspartic acid component is essential for the antibiotic activity of Laspartomycin C and its derivatives.
• Laspartomycin C and its modified forms show promise for combating infections caused by antibiotic-resistant bacteria, including MRSA and VRE.